<DOC>
	<DOCNO>NCT01614743</DOCNO>
	<brief_summary>This double-blinded , randomized placebo control pilot study compare efficacy safety incobotulinumtoxinA versus saline injection cheek region patient rosacea . The pilot study enroll treat total 10 subject present rosacea cheek area . Upon study entry , subject randomize receive treatment incobotulinumtoxinA bacteriostatic saline cheek area . Study treatment prepare unblinded designee Physician Investigator ( PI ) subject remain blind duration study . At 16 week visit , control subject enter rescue arm portion study study subject receive treatment incobotulinumtoxinA cheek area .</brief_summary>
	<brief_title>A Double-Blinded , Randomized Placebo Controlled Pilot Study Comparing Efficacy Safety IncobotulinumtoxinA Versus Saline Injections Cheek Region Patients With Rosacea</brief_title>
	<detailed_description />
	<mesh_term>Rosacea</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<criteria>1 . Males females 18 65 year age . 2 . Subjects present rosacea cheek area . 3 . Willingness ability comply protocol requirement , include return followup visit abstain exclusionary procedure duration study . 4 . Subjects childbearing potential must negative urine pregnancy test result Visit 1 willing able use acceptable method birth control ( e.g. , barrier method use spermicidal agent , hormonal method , IUD , surgical sterilization , abstinence ) study . Women consider childbearing potential one follow document medical history : postmenopausal least 12 month prior study drug administration without uterus and/or ovary bilateral tubal ligation least 6 month prior study drug administration . absence physical condition accord PI 's discretion 5 . Willingness ability provide write photo consent adherence photography procedure ( i.e. , removal jewelry makeup ) . 6 . Willingness ability provide write informed consent prior performance study related procedure . 1 . Subjects pregnant , nursing , plan become pregnant , and/or use reliable form birth control . 2 . Subjects know allergy sensitivity component study medication anesthesia . 3 . Topical oral rosacea treatment within past 2 week . 4 . Subjects significant systemic illness illness localize area treatment . 5 . Botulinum toxin face within past 6 month . 6 . Significant concurrent illness diabetes , epilepsy , lupus , congestive heart failure . 7 . Concurrent skin condition affect area treat . 8 . Prior surgery area treat within 3 month initial treatment study . 9 . History evidence keloid hypertrophic scar . 10 . Subjects currently use aminoglycoside antibiotic , curarelike agent agent might interfere neuromuscular function . 11 . Subjects diagnosis Myasthenia Gravis , EatonLambert Syndrome , Amyotrophic Lateral Sclerosis , disease might interfere neuromuscular function current facial palsy . 12 . Current history chronic drug alcohol abuse . 13 . Concurrent therapy , investigator 's opinion , would interfere evaluation safety efficacy study medication . 14 . Subjects , Investigator 's opinion , history poor cooperation , nonÂ¬compliance medical treatment unreliability . 15 . Enrollment active study involve use investigational device drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Rosacea</keyword>
</DOC>